Membranous nephropathy induced by pegylated interferon α-2a therapy for chronic viral hepatitis B

Clinical Nephrology

Volumn 77, Issue 6, 2012, Pages 496-500

  Tsai, Ming Shien ^a   Chen, Jui Hao ^a   Fang, Yu Wei ^a   Yang, An Hang ^b   Chang, Chung Hsin ^a,c  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatitis B virus; Interferon; Membranous nephropathy; Nephrotic syndrome; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN; DIURETIC AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANASARCA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHRONIC HEPATITIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; HEPATITIS B; HUMAN; LEG EDEMA; LIVER FUNCTION TEST; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MICROSCOPY; NEPHROTIC SYNDROME; PHYSICAL EXAMINATION; PROTEINURIA; REMISSION; SIDE EFFECT; ULTRASTRUCTURE ANALYSIS AND ELECTRON MICROSCOPY; URINALYSIS; WEIGHT GAIN; BIOPSY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SUBSTITUTION; IMMUNOHISTOCHEMISTRY; KIDNEY; PATHOLOGY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTIVIRAL AGENTS; BIOPSY; CYCLOSPORINE; DRUG SUBSTITUTION; GLOMERULONEPHRITIS, MEMBRANOUS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; KIDNEY; MALE; NEPHROTIC SYNDROME; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84864569772     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107903     Document Type: Article

References (26)

1. Fisher ME, Rossini M, Simmons E, Harris RC, Moeckel G, Zent R. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy. Am J Kidney Dis. 2004; 44: 567-573.
2. Bremer CT, Lastrapes A, Alper AB Jr, Mudad R. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature. Am J Clin Oncol. 2003; 26: 262-264. doi: 10.1097/01. COC.0000020649.11411.2B.
3. Auty A, Saleh A. Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. Can J Neurol Sci. 2005; 32: 366-368.
4. Tovar JL, Buti M, Segarra A, Majó J, Esteban R. De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. Int Urol Nephrol. 2008; 40: 539-541.
5. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004; 350: 1118-1129.
6. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130: 678-686.
7. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol. 1999; 30: 536-550.
8. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother. 2008; 62: 224-228.
9. Alazawi W, Foster GR. Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis. 2008; 21: 508-515.
10. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119: 312-323.
11. Chevaliez S, Pawlotsky JM. Interferons and their use in persistent viral infections. Handb Exp Pharmacol. 2009; 189: 203-241.
12. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA Jr, Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis. 2000; 35: 878-883.
13. Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol. 1997; 8: 664-674.
14. Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int. 1983; 24: 377-385.
15. Takekoshi Y, Tochimaru H, Nagata Y, Itami N. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl. 1991; 35: S34-S39.
16. Kuroki A, Shibata T, Honda H, Totsuka D, Kobayashi K, Sugisaki T. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002; 41: 936-942.
17. Peters M, Ambrus JL, Zheleznyak A, Walling D, Hoofnagle JH. Effect of interferon-alpha on immunoglobulin synthesis by human B cells. J Immunol. 1986; 137: 3153-3157.
18. Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest. 1985; 75: 1908-1913.
19. Conlon KC, Urba WJ, Smith JW II, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alphainterferon therapy. Cancer. 1990; 65: 2237-2242.
20. Rönnblom LE, Alm GV, Öberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991; 115: 178-183.
21. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol. 1995; 13: 2401-2407.
22. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997; 26: 206-210.
23. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000; 43: 1431-1442.
24. Lai KN, Lai FM, Tam JS. Comparison of polyclonal and monoclonal antibodies in determination of glomerular deposits of hepatitis B virus antigens in hepatitis B virus-associated glomerulonephritides. Am J Clin Pathol. 1989; 92: 159-165.
25. Hsu HC, Wu CY, Lin CY, Lin GJ, Chen CH, Huang FY. Membranous nephropathy in 52 hepatitis B surface antigen (HBsAg) carrier children in Taiwan. Kidney Int. 1989; 36: 1103-1107.
26. Lin CY. Hepatitis B virus-associated membraneous nephropathy: clinical features, immunological profiles and outcome. Nephron. 1990; 55: 37-44.